Zobrazeno 1 - 10
of 174
pro vyhledávání: '"Juanita Lopez"'
Autor:
Mary Van Zyl, Anne Barell, Bridget Cooley, Janet Hanwell, Josie Parlak, Udai Banerji, Johann De Bono, Adam Sharp, Juanita Lopez, Nicolo Matteo Luca Battisti, Anna Minchom
Publikováno v:
Cancer Reports, Vol 7, Iss 6, Pp n/a-n/a (2024)
Abstract Background Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials. Aims We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older w
Externí odkaz:
https://doaj.org/article/898ed05cc677458a94115355b7e29a02
Autor:
Markus Joerger, Emiliano Calvo, Heinz Läubli, Juanita Lopez, Elena Garralda, Dagmar Hess, Elena Corral de la Fuente, Christoph Bucher, Guzman Alonso, Sangeeta Jethwa, David König, Vicky Sanchez Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the
Externí odkaz:
https://doaj.org/article/c922b1eb4e8b44009c63d9e58c5680a1
Autor:
Preethika Mahalingam, Sam Smith, Juanita Lopez, Rajaei K Sharma, Thomas Millard, Khin Thway, Cyril Fisher, David A Reardon, Robin Jones, Andrew G Nicholson, David Cunningham, Liam Welsh, Bhupinder Sharma
Publikováno v:
Rare Tumors, Vol 15 (2023)
Myxopapillary ependymoma (MPE) is a primary tumor of the central nervous system (CNS), characteristically an indolent malignancy involving the spinal conus medullaris, Filum terminale or cauda equina. We present a rare case of MPE, recurrent in the p
Externí odkaz:
https://doaj.org/article/83463f5c2d154c77a10b96c61be09d20
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor typ
Externí odkaz:
https://doaj.org/article/685e419c10a44010b20b8a8800523aa7
Autor:
Robert Brown, Christina Yap, Johann De Bono, Malaka Ameratunga, Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Chloe Baker, Nina Tunariu, Suzanne Carreira, Udai Banerji, Juanita Lopez, Alison Turner, Wentin Chen, Abhijit Pal, Dionysis Papadatos-Pastos, Toby Prout, Maxime Chénard-Poirier, Andra Curcean, Nahal Masrour, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Mona Parmar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/b9a84246b2264ed1b2c2acbbf2f19d79
Autor:
Homer Adams, Patricia LoRusso, Juanita Lopez, Melissa Johnson, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Jessica Bauman, Daniel Haggstrom, Eleni Lagkadinou, Gaurav Bajaj, Yali Fu, Kristoffer Rohrberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5504cd1e2ae94610a037c158735c29e7
Autor:
Christina Yap, Deme Karikios, Johann De Bono, Anna Minchom, Udai Banerji, Juanita Lopez, Sarah Stapleton, Frances Boyle, Abhijit Pal, Julia Lai-Kwon, Robert Daly, Dimitrios Magkos, Bindumalini Rao Baikady
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
Introduction Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures—this is reflected in the increasing length of participant information sheets (PIS). Informed consent for early p
Externí odkaz:
https://doaj.org/article/b5e4da0c65834b85bca76b00cf5340d0
Autor:
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur Frankel, Peter Schmid, Kathleen Moore, William McCulloch, Katharine Grimmer, Marie O'Farrell, George Kemble, Howard Burris
Publikováno v:
EClinicalMedicine, Vol 34, Iss , Pp 100797- (2021)
Background: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. Methods: This completed open-la
Externí odkaz:
https://doaj.org/article/2febb21dda0b44dcb8507b74f4dd5b16
Autor:
Andrea Biondo, Abhijit Pal, Ruth Riisnaes, Rajiv Shinde, Crescens Tiu, Fran Lockie, Chloe Baker, Claudia Bertan, Mateus Crespo, Ana Ferreira, Rita Pereira, Ines Figueiredo, Susana Miranda, Bora Gurel, Suzanne Carreira, Udai Banerji, Johann de Bono, Juanita Lopez, Nina Tunariu, Anna Minchom
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100309- (2021)
ABSTRACT: Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research tissue biopsies. Re
Externí odkaz:
https://doaj.org/article/7ee213af1fdd4bdb8f1be7e81291035f
Autor:
Johann De Bono, Nicos Fotiadis, Sanjay Popat, Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Andrew Wotherspoon, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Matt Clarke, Chloe Baker, Joo Ern Ang, Nina Tunariu, Suzanne Carreira, Mary O'Brien, Udai Banerji, Juanita Lopez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge.Case presentation A 77-year-old woman with advanced epithelioid mesothelioma extensively pretre
Externí odkaz:
https://doaj.org/article/7e62949f48524365b46f3e0bf7017a58